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Abstract
Background: HIV binding has been demonstrated in erythrocytes from HIV-positive and HIV-negative individuals. However,
the presence of immunoglobulins G anti-HIV (IgG anti-HIV) in erythrocytes from HIV-positive individuals is still to be
elucidated. Moreover, the capacity of erythrocytes from HIV-positive individuals to capture an additional amount of HIV has
not been studied. Indeed, it is unknown if HIV binding to erythrocytes in HIV-positive persons could have consequences on
the cell-free infectious virus available.
Methodology/Principal Findings: IgGs anti-HIV associated to erythrocytes were found in 77.3% (58/75) of the HIV-positive
individuals studied and the IgGs anti-gp160 and anti-p24 were the most frequently found. We found a positive association
between detectable plasma viral load (pVL) and presence of IgGs anti-HIV associated to erythrocyte (p,0.005), though the
anti-p24/160 were present with or without detectable pVL. The HIV capture capacity was higher in erythrocytes from HIV-
positive than HIV-negative individuals (p,0.0001). Furthermore, among the HIV-positive individuals the higher viral capture
capacity was associated with the presence of anti-gp160/gp120 on erythrocytes. Moreover, the viral capture by erythrocytes
was independent of pVL (rho = 0.022, p= 0.8817). Additionally, reduction of cell-free infectious virus and available viral load
was observed in the presence of erythrocytes from HIV-positive individuals.
Conclusions/Significance: Results suggest that in HIV-positive individuals, erythrocytes are capable of capturing high
amounts of HIV by the presence of IgGs anti-gp160/120 on their membranes and this may produce a reduction in the
available free virus. Finally, the current measurement of pVL would underestimate the real viral quantity due to the HIV
binding through specific antibodies to erythrocytes.
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Introduction
During persistent chronic viral infections, antibody and virus
production occurs simultaneously, creating conditions for immune
complexes formation and the subsequent adherence to erythro-
cytes (immune-adherence) [1,2]. Immune complexes, namely
antigens opsonized by antibodies and complement, are bound to
erythrocytes through specific interactions of the complement
protein C3b with the erythrocyte complement receptor 1 (CR1 or
CD35). Eventually, erythrocytes carried in the bloodstream pass
through the spleen and liver where macrophages take up the
immune complexes [3,4].
Human immunodeficiency virus type 1 (HIV) particles are
known to be capable of binding to erythrocytes in HIV-negative
individuals in vitro by at least three mechanisms: 1) binding of
immune complexes through the CR1 receptor, 2) binding of HIV
to CR1 by complement proteins but in absence of antibodies, and
3) direct binding of HIV to Duffy antigen receptor for chemokines
(CD55 or DARC) present on erythrocytes [5–10].
Recently we have shown the presence of HIV viral load and
p24-antigen on erythrocytes from HIV-positive individuals even
in patients with undetectable plasma viral load (pVL) [1]. In that
study, presence of p24-antigen was found in more than 70% of
the patients with detectable pVL and in some patients with
undetectable pVL [1]. Moreover, Hess et al., 2002 [11] reported
detectable HIV viral loads in purified erythrocytes from a group
of patients under highly active antiretroviral therapy for a long
period of time.
Several authors have suggested that erythrocyte-bound HIV
might comprise an important surface reservoir for trans infection of
permissive cells [9–13]. Furthermore, it has been demonstrated
that HIV infects CD4-positive cells approximately 100-fold more
efficiently when it is associated to erythrocyte than when it is
present as cell free viral particles [9,10]. Besides, the virus bound
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e45808
to erythrocytes may be less sensitive to neutralization mediated by
some specific antibodies [14]. Altogether, these data highlight the
relevance in understanding the HIV-erythrocyte interaction
during the HIV pathogenesis.
One of the proposed mechanisms for HIV binding to
erythrocytes involves immune complexes [5–7,13]. However, the
presence and pattern of immunoglobulins G anti HIV (IgG anti-
HIV) in erythrocytes from HIV-positive individuals is still to be
demonstrated. Moreover, in spite that erythrocytes are virus
carriers, the capacity of erythrocytes from HIV-positive individuals
to attach virus and/or antigen at the cell surface has not been
studied. Indeed, it is unknown if HIV binding to erythrocytes of
HIV-positive individuals could quantitatively affect the cell-free
infectious virus available.
In this study we demonstrate the presence of IgGs anti-HIV
associated to erythrocytes from HIV-positive individuals. In-
terestingly, we found that erythrocytes from HIV-positive individ-
uals have higher capacity of viral capture than erythrocytes from
HIV-negative individuals. Furthermore, this higher capacity was
associated with the presence of the IgG anti-gp160/gp120 in
erythrocytes. Finally, erythrocytes quantitatively decrease the
available cell-free infectious virus.
Results
IgGs Anti-HIV are Present on Erythrocytes from HIV-
positive Individuals
In order to investigate the presence and pattern of IgGs anti-
HIV in erythrocytes from HIV-positive individuals, blood samples
of 75 individuals were evaluated. IgGs anti-HIV were determined
by western blot assay in: purified erythrocytes (IgG anti-HIV-E),
supernatant of the last erythrocytes washing (IgG anti-HIV-W)
and plasma (IgG anti-HIV-P). One or more IgG anti-HIV-E
antibodies were found in 77.3% (58/75) of the studied individuals.
IgGs anti-HIV antibodies most frequently associated to erythro-
cytes were anti-gp160 in 84.5% (49/58), anti-p24 in 63.8% (37/
58), anti-p34 in 39.6% (23/58), anti-p68 in 34.5% (20/58), anti-
gp41 in 25.8% (15/58), anti-p55 in 22.4% (13/58), anti-gp120 in
18.9% (11/58), anti-p52 in 13.8% (8/58), anti-p40 in 6.9% (4/58)
and anti-p18 in 1.7% (1/58) (Table S1). Anti-gp41 and anti-
gp120 antibodies were found in those samples where anti-gp160
was also detectable. In contrast, presence of anti-gp160 was not
always accompanied by presence of anti-gp120 and/or anti-gp41
(Table S1).
Consecutively, the association between pVL and presence of
IgG anti-HIV-E was studied. To accomplish this objective, pVL
was determined in blood samples of the 75 individuals listed
above. Only 14 out of 25 individuals, with undetectable pVL (,50
copies per ml), presented IgG anti-HIV-E. On the contrary, IgG
anti-HIV-E were detected in 44 out of 50 individuals that
presented detectable pVL ($50 copies per ml) and a significant
positive relationship between detectable pVL and the presence of
IgG anti-HIV-E was found (p,0.005). Anti-p24 and anti-gp160
antibodies were present on erythrocytes in patients with or without
detectable pVL. However, all the other antibodies mentioned
above were found only among individuals with detectable pVL.
Moreover, a significant positive relationship was observed between
detectable pVL and presence of anti-gp160 (p,0.05), anti-gp120
(p,0.05), anti-p68 (p,0.0005), anti-p55 (p,0.005), anti-p52
(p,0.05), anti-gp41 (p,0.005) and anti-gp34 (p,0.0005) in
erythrocytes. No significant relationship was found for anti-p40,
anti-p24 and anti-p18 (Table S1).
While all IgGs anti-HIV were detected in plasma, the pre-
dominant pattern on erythrocytes was anti-gp160 and/or anti-
p24. It is important to highlight, that no IgG anti-HIV was ever
detected in the supernatant of the last erythrocyte washing (IgG
anti-HIV-W). This last demonstrates that purified erythrocytes did
not contain contaminating IgG anti-HIV from other blood
fractions such as plasma (Figure 1).
Since different IgG anti-HIV patterns were found in plasma and
erythrocytes from the same patients, we evaluated the selectivity of
IgG anti-HIV adherence to erythrocyte. To accomplish this goal,
we compared the IgG anti-HIV pattern in plasma and
erythrocytes at the same concentration in eight samples from
HIV-positive individuals (see materials and methods section).
Notably, we could not found a correspondence between IgG anti-
HIV pattern in erythrocytes and plasmas at same concentration of
IgGs (Figure S1). Altogether, these results demonstrate the
existence of a selective IgG anti-HIV adherence to erythrocytes of
HIV-positive individuals.
p24-antigen Detection on Erythrocytes is Accompanied
by Presence of IgG Anti-HIV
Recently, we have demonstrated the presence of p24-antigen in
erythrocytes from HIV-positive individuals [1]. Therefore, in
order to determine if detection of p24-antigen in erythrocytes (Ag-
E) implies presence of IgGs anti-HIV-E, the pattern of antibodies
present on erythrocytes was determined in samples of 12
Figure 1. Anti-HIV antibodies pattern associated to erythrocytes. IgG anti-HIV were determined by western blot in: plasma (IgG anti-HIV-P),
purified erythrocytes (IgG anti-HIV-E), and supernatant of the last wash of erythrocytes purification process (IgG anti-HIV-W). Figure shows
a representative pattern of IgG anti-HIV in erythrocytes from HIV-positive individuals. Presence of IgG anti-gp160, IgG anti-p24 and IgG anti-p34 in
erythrocytes of one patient is observed.
doi:10.1371/journal.pone.0045808.g001
HIV Capture by Erythrocytes
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individuals who had detectable Ag-E. We found that all of these
individuals presented at least one IgG anti-HIV in erythrocytes.
Determinations showed presence of anti-gp160 in 11 out of the 12
individuals, 6 presented IgG anti-p24 and 6 IgG anti-p34 (Table
S1). Although, there are not enough determinations for a statistical
analysis, these results suggest a possible association between
detection of Ag-E and presence of IgG anti-HIV on erythrocyte
membrane.
Erythrocytes from HIV-positive Individuals Possess Higher
HIV Capture Capacity than Erythrocytes from HIV-
negative Individuals
Erythrocytes are in high number providing a large surface in the
bloodstream. Besides, presence of HIV-RNA [1,11], p24-antigen
[1] and IgG anti-HIV was shown on erythrocytes from HIV-
positive individuals. In order to establish whether erythrocytes
from HIV-positive individuals are still capable to attach additional
virus and/or antigen at the cell surface, we analyzed HIV capture
by erythrocytes, pVL and IgG anti HIV-E in 48 blood samples
from HIV-positive (48 of the 75 belonging to Table S1) and 15
from HIV-negative individuals.
In erythrocytes from HIV-positive individuals an HIV capture
higher than 20% was found in the 56% (27/48) of the samples
with a mean of 33.82% (Figure 2 A and B, Table S1). No
correlation was observed between the HIV capture capacity by
erythrocytes and the pVL value (rho = 0.022, p= 0.8817). This
result demonstrates that the erythrocyte viral capture occurs
independently of the pVL (Figure 2A). In contrast, the HIV
capture capacity by erythrocytes from HIV-negative individuals
was less than 20% in all cases, with a mean of 11.95%
(Figure 2B). Analyzing both groups, a significant difference was
found between the means of HIV capture capacity by erythrocytes
in each group (p,0.0001). These results suggest that erythrocytes,
in HIV-positive individuals, not only are in circulation with HIV/
antigen bound in their membranes, but are also able to capture an
additional amount of virus.
The IgG Anti-gp160/120 is Responsible for the Higher HIV
Capture Capacity of Erythrocytes from HIV-positive
Individuals
Since erythrocytes from HIV-positive individuals possess higher
HIV capture capacity we wondered if this fact is related to the
presence of IgGs anti-HIV on erythrocytes. In this regard, we
could not find a relationship between the presence of IgG anti-
HIV-E and a HIV capture capacity higher than 20% (p.0.5)
(Figure 2C). Indeed, we did not find a statistical relationship
between the HIV capture capacity mean level and the presence of
IgG anti-HIV-E (p.0.05) (Figure 2C). Nevertheless, there is an
extremely significant difference between the means of HIV
capture capacity in individuals with (N = 25, mean 49.22%) and
without (N = 23, mean 17.11%) IgG anti-gp160 associated to
erythrocyte (p,0.0005) (Figure 2D). From those patients with
IgG anti-gp160, 20 out of 25 presented an HIV capture capacity
higher than 20% and 13 higher than 50% (Figure 2D). On the
other hand, from the 23 individuals without IgG anti-gp160, only
7 presented values higher than 20% and 3 over 50% (Figure 2D).
These data strongly suggest that, in erythrocytes from HIV-
positive individuals, exist a positive association between presence
of IgG anti-gp160 and HIV capture capacity.
The gp160 antigen is a precursor that is cleaved in order to
form the gp120 and gp41 proteins. Therefore, these three proteins
share several epitopes. To elucidate whether HIV capture by
erythrocytes relies on the IgG anti-gp120, an inhibition assay of
the viral capture was performed in erythrocytes from 11 HIV-
positive individuals (in all cases the IgG anti HIV-E pattern was
determined prior to viral capture assay). Figure 3A shows that
incubation of erythrocytes with recombinant gp120 protein
decreases the HIV capture (p,0.05, two-way ANOVA with
random effects). Moreover, the inhibitory effect varied according
to the subject from whom erythrocytes were obtained (p,0.05,
two-way ANOVA with random effects). Since erythrocytes with
IgG anti-gp120 presented higher viral capture, the inhibitory effect
was markedly more important in this group than in the group of
erythrocytes without IgG anti-gp120 (p,0.05, repeated measures
analysis) (Figure 3 B and C). Presented data only shows the
results obtained for gp120 IIIB, although similar results were
obtained with the MN and CM variants (data not shown). In
summary, higher HIV capture is associated to individuals with
IgG anti-gp120 on their erythrocytes.
Loss of HIV Infectivity and Viral Load is due to the
Presence of Erythrocytes
Given that it has been demonstrated that erythrocytes are
capable of capturing HIV, we wondered whether erythrocytes
may affect HIV infectivity in presence of antibodies from HIV-
positive individuals. In order to address this issue, plasma dilutions
from 14 HIV-positive individuals were used as source of HIV-
specific antibodies and then incubated with CXCR4-tropic strains
of HIV IIIB.
In absence of erythrocytes, the reduction of HIV infectivity in
plasma was significantly greater when complement was present
than when it was inactivated (p,0.05, Wilcoxon signed-rank test,
mean 678 vs 244), as reported by Huber et al., 2006 [15]
(Figure 4A). The presence of erythrocytes, concomitantly in-
cubated with complement, led to a loss of HIV infectivity
considered extremely significant compared to erythrocytes in-
cubated with inactivated complement (mean 3,675 vs. 210,
p,0.0005, Wilcoxon signed-rank test) Figure 4B. More impor-
tantly, the loss of HIV infectivity in presence of complement was
exacerbated when erythrocytes were also present (639 vs. 3,457,
p,0.0005 Wilcoxon signed-rank test) (Figure 4C). On the other
hand, when complement was inactivated, the loss of HIV
infectivity was not affected by the presence or the absence of
erythrocytes (mean 210 vs. 244, p.0.5 Wilcoxon signed-rank test)
and it was always lower than when the non-inactivated comple-
ment was present (Figure 4D).
In another series of experiments, the presence of erythrocytes
accompanied of immunoglobulins anti-HIV and complement, was
sufficient to produce a significant decrease in HIV viral load (viral
particle) (p,0.05 Wilcoxon signed-rank test) (Figure 5).
These results demonstrate that complement and erythrocytes
play a key role in the HIV infectivity and suggest that erythrocyte-
mediated sequestering of HIV particles may be relevant to the
plasma viral load of patients.
The Presence of Erythrocytes from HIV-positive
Individuals Produces Loss of HIV Infectivity
We have demonstrated the ability of erythrocytes from HIV-
positive individuals to capture free HIV. This remarkable property
is complemented by the fact that erythrocytes from HIV-negative
individuals are able to decrease the viral load and HIV infectivity.
Those results led us to study the ability of erythrocytes from HIV-
positive individuals to reduce the HIV infectivity. With that
purpose, erythrocytes from HIV-positive individuals were in-
cubated with a known amount of virus in a similar way as that it
was explained in the last section but in absence of immunoglo-
HIV Capture by Erythrocytes
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bulins anti-HIV and complement. Figure 6 shows that HIV
incubation with erythrocytes from HIV-positive individuals
significantly decreased the HIV titer in the medium (p,0.001).
The erythrocytes from HIV-negative individuals also reduced the
HIV titer (p,0.01) and despite that this reduction looks lower than
data from HIV-positive individuals, they were not statistically
different (p.0.05) (Figure 6).
Discussion
The present study showed that IgG anti-HIV were associated to
erythrocytes in 77.3% (58/75) of HIV-positive individuals
suggesting that viral adherence through antibodies may occur in
vivo. The most frequently associated to erythrocytes was anti-
gp160, followed by anti-p24. The presence of IgG anti-gp120 or
IgG anti-gp160 in erythrocytes may reflect the presence of
erythrocyte-associated immune complexes formed by viral parti-
cles and/or soluble antigens. Though, p24-antigen may be not
associated to viral particles in plasma [16–18] IgG anti-p24
associated to erythrocytes could be present even in individuals with
undetectable viral loads.
A detectable pVL indicates that viral particles are circulating
where the virus could be recognized and coated by specific
antibodies and complement proteins to finally bind to erythro-
cytes. In this regard the association between the presence of IgGs
anti-HIV on erythrocytes and detectable pVL suggests the
presence of viral particles and/or viral antigens on erythrocytes.
More significant is the association between the presence of IgG
anti-gp160 and detectable pVL because it would reflect the
presence of viral particles associated to erythrocytes through
immune-complexes. On the other hand, the presence of IgG anti-
p24 was not associated to detectable pVL. Indeed the erythrocyte-
associated p24 antigen is not associated to detectable pVL [1].
This coincidence is striking due to the fact that in both cases it
Figure 2. Capture of HIV by erythrocytes from HIV-positive individuals. Plots show capture of HIV by erythrocytes (percentage of p24-
antigen bound to erythrocytes, viral capture assay) from 48 HIV-positive individuals (48 of 75 belonging to Table S1) and 15 HIV-negative individuals.
Each bar represents an individual. (A) HIV capture by erythrocytes according to plasma viral load. Range of plasma viral load is indicated at the top.
Individuals are located according to the value of plasma viral load at the time of study. No correlation is observed between the ability of HIV capture
by erythrocytes and plasma viral load of patients (rho = 0.022, p= 0.8817, correlation was evaluated using Spearman’s rank correlation),
demonstrating that viral capture by erythrocytes occurs independently of plasma viral load. (B) HIV capture by erythrocytes from 48 HIV-positive and
15 HIV-negative individuals. Individuals are located in increasing values of viral capture capacity. Both groups show a significant difference between
mean levels of HIV capture (p,0.0001). (C) The 48 HIV-positive individuals are grouped according to the presence (+ IgG anti-HIV-E, N= 32) or
absence (- IgG anti-HIV-E, N= 16) of at least one IgG anti-HIV associated to erythrocytes. No statistical difference was found between presence of IgG
anti-HIV-E and a viral capture .20% by erythrocytes (p.0.5). (D) The 48 HIV-positive individuals are grouped according to the presence (+ IgG anti-
gp160-E, N= 25) or absence (- IgG anti-gp160-E, N = 23) of IgG anti-gp160 associated to erythrocytes. Erythrocytes with presence of IgG anti-gp160
show an HIV capture higher than 20% (p,0.0005).
doi:10.1371/journal.pone.0045808.g002
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seems that detectable pVL might not be related to p24-antigen or
IgG anti-p24 in erythrocytes.
Altogether, the presence of IgG anti-HIV in erythrocytes from
HIV-positive individuals, supported by previous data about p24-
antigen [1] and HIV-RNA [1,11] detected in erythrocytes,
suggests that virus and/or viral antigens bind to erythrocytes by
immunoadherence in HIV-positive individuals.
Only 14 patients of the studied population presented IgG anti-
HIV on erythrocytes with undetectable pVL (Table S1). This
result can be understood taking into account, as explained above,
that it is not necessary a detectable pVL for antigen detection on
erythrocytes [1]. We also observed that some individuals have had
a detectable pVL without detection of IgG anti-HIV on
erythrocytes (Table S1). This fact could indicate a different viral
Figure 3. Inhibition of HIV capture by recombinant gp120. (A) Percentage of HIV capture by erythrocytes from HIV-positive individuals (11 of
75 belonging to Table S1). Erythrocytes were previously incubated with soluble gp120 (Inhibition of viral capture assay, dark gray bars) or without
gp120 (viral capture assay, light gray bars). HIV capture by erythrocytes was inhibited by viral gp120 (p,0.05) and the variation between individuals
was significant (p,0.05) (two-way ANOVA with random effects). This result indicates that the large-scale inhibitory effect varies according to the
subject from whom erythrocytes were obtained. (B) The table lists IgG anti-HIV antibodies present in the erythrocytes of the 11 individuals. All of
them have IgG anti-gp160, and 6 individuals with IgG anti-gp120 also present IgG anti-gp41 on their erythrocytes (patients 62, 59, 42, 31, 71 and 68).
(C) The mean percentage of viral capture of HIV by erythrocytes with or without inhibition with soluble gp120 is plotted in individuals who present
IgG anti-gp120 in erythrocytes (+ IgG anti-gp120-E, line with square) and in individuals who do not present IgG anti-gp120 in erythrocytes (- IgG anti-
gp120-E, line with rhomb). The inhibitory effect mainly occurs in individuals with IgG anti-gp120 on their erythrocytes (p,0.05, repeated measures
analysis).
doi:10.1371/journal.pone.0045808.g003
HIV Capture by Erythrocytes
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clearance or a viral capture independent of the presence of
antibodies in erythrocytes [9,10].
The data support that the erythrocytes from HIV-positive
individuals may not only have associated RNA-HIV, p24-antigen
[1,11] and IgG anti-HIV but also bear the capacity to capture
additional HIV to its membrane. The viral capture capacity assay
performed on erythrocytes from a group of HIV-positive
individuals showed that about 50% of them captured more than
20% of virus. Moreover, we ruled out the possibility that p24-
antigen on patients’ erythrocytes interfere with the capture
capacity assay. On the contrary, erythrocytes from HIV-negative
individuals always capture a maximum of 19.5%. These observa-
tions differ from that observed by Beck et al., 2009 [10], who found
that erythrocytes from non-infected individuals could capture up
to 6% of HIV. This could be explained since lower quantities of
virus stock enriched in particles were used in the present study.
Of note is that the HIV capture capacity by erythrocytes from
HIV-positive individuals was not related to the value of pVL.
Figure 4. Presence of erythrocytes contribute to the loss of HIV infectivity. Figure shows neutralization titers, expressed as the inverse of
the highest dilution that is able to inhibit syncytia formation (loss of infectivity) in MT-2 cells. Plasma dilutions from 14 HIV-positives individuals (Ig) (as
a source of HIV-specific antibodies) were incubated with CXCR4-tropic strain of HIV IIIB (HIV) in presence of: normal human serum as source of
complement (C) (HIV + Ig + C) or inactivated normal human serum (Ci) (HIV + Ig + Ci). Each of these was exposed to erythrocytes from HIV-negative
individuals (E) (HIV-Ig-C +E or HIV-Ig-Ci + E). The remaining infectivity in supernatants of each incubation was measured. Data points are means of
three independent experiments with plasma from the same patient. (A) In the absence of erythrocytes, the loss of HIV infectivity in plasma was
significantly greater when complement was present than when it was inactivated (p,0.05, Wilcoxon signed-rank test). (B) The presence of
erythrocytes incubated with complement led to a loss of HIV infectivity considered extremely significant when compared to erythrocytes incubated
with inactivated complement (p,0.0005, Wilcoxon signed-rank test). (C) Loss of infectivity in the presence of complement was exacerbated when
erythrocytes were also present (p,0.0005 Wilcoxon signed-rank test). (D) The loss of infectivity in the presence of inactivated complement was not
affected by the presence or absence of erythrocytes (p.0.5 Wilcoxon signed-rank test). Results demonstrate that the loss of HIV infectivity is
increased in vitro in an environment where erythrocytes are present.
doi:10.1371/journal.pone.0045808.g004
HIV Capture by Erythrocytes
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e45808
Therefore, the HIV bound to erythrocytes was not in line with the
circulating viral particles. This suggests that erythrocytes are not
saturated in vivo, thus additional virus binding and virus clearance
may occur simultaneously in the patients.
The presence of IgG anti-gp160 in erythrocytes yielded
a statistical increase in HIV capture capacity (p,0.0005). When
erythrocytes were blocked by soluble gp120, the viral capture
decreased considerably and this effect was marked in those
individuals with IgG anti-gp120 in erythrocytes (Figure 3).
However, as the inhibition by recombinant gp120 was never
completed other mechanisms such as HIV binding to erythrocytes
by DARC antigen [9,10], could be involved. Of note, the capture
inhibition assay was performed with three different strains of
gp120 (IIIB, MN and CM) with similar results. This suggests that
gp120-mediated HIV capture inhibition may be not virus strain
specific.
Note that patients 65 and 27 (Figure 3B) have the same
western blot pattern, neither of them show presence of anti-gp120
and anti-gp41 IgGs. Nevertheless, both of them have presence of
IgG anti-gp160. Since gp160 is the precursor of gp120 and gp41,
a possible explanation is that such antibodies are present but they
are not detected due to higher affinity to gp160.
The proposed mechanism for erythrocyte-mediated HIV
capture is that the circulating virus is exposed to recognition by
specific antibodies and afterwards it is attacked by the complement
system. This induces the formation of circulating immune
complexes, their binding to erythrocytes and posterior depuration.
Those erythrocytes carrying immune complexes, with antibodies
in excess, expose free paratopes which could allow additional virus
capture. Consequently, the viral capture by erythrocytes in HIV-
positive individuals could play an important role in the clearance
of free virus and its delivery to macrophages in spleen and liver
[4]. Even more, erythrocytes might bind HIV virions which are
then potentially available for trans infection of permissive target
cells.
Reduction of viral infectivity by erythrocytes has already been
suggested for type 5 adenovirus (Ad5) [19]. It has been
demonstrated that erythrocytes efficiently sequester Ad5, reducing
its extravasation and infectivity [19]. Additionally, similar results
Figure 5. Loss of viral load by presence of erythrocytes. Figure
shows viral load (copies/ml) of plasmas from 6 HIV-positive individuals
(Ig), as a source of HIV-specific antibodies, incubated with HIV IIIB (HIV)
in presence of normal human serum as complement source (C) and in
presence (+E) or absence of erythrocytes. Viral load was determined in
each supernatant. Data points are means of three independent
experiments with plasma from the same patient. The difference
between the value of viral load in presence and absence of erythrocytes
was compared using Wilcoxon signed-rank test.
doi:10.1371/journal.pone.0045808.g005
Figure 6. Loss of HIV infectivity by presence of erythrocytes from HIV-positive individuals. HIV IIIB (HIV) was incubated with erythrocytes
from HIV-positive (HIV + E HIV-positive individuals) or HIV-negative (HIV + E HIV-negative individuals) individuals. The figure shows the titers of infectious HIV in
each supernatant. A significant reduction in the titer of HIV is observed in the presence of erythrocytes from HIV-positive (p,0.001) or HIV-negative
individuals (p,0.01). No statistical difference is observed in HIV titre reduction between erythrocytes from HIV-positive versus HIV-negative
individuals (p.0.05). Differences were compared using Kruskal-Wallis Test.
doi:10.1371/journal.pone.0045808.g006
HIV Capture by Erythrocytes
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have been reported for parvovirus B19 [20]. These facts highly
support our results about significant reduction of HIV infectivity in
plasma when it is incubated with erythrocytes. Circulating HIV is
exposed to neutralization and virolysis by the complement system
[15], in an environment where a high number of erythrocytes are
capable of capturing HIV. The current study demonstrates that in
the presence of antibodies and complement, erythrocytes contrib-
ute to the reduction of the viral load and HIV infectivity. Although
this study was not intended to elucidate whether the erythrocyte-
mediated reduction of HIV infectivity is due to direct binding of
HIV to erythrocytes or to an enhanced neutralization and/or
complement-mediated lysis, the viral capture assays suggest the
first option where the erythrocytes play a major role.
The results presented here suggest that the current measure-
ment of pVL in HIV-positive individuals would underestimate the
real viral quantity due to the HIV binding to erythrocytes
mediated by complement and/or antibodies. On the contrary, the
amount of antibodies bound to erythrocytes would not alter the
detection of plasma antibodies in HIV-positive patients. As it was
presented in this work, the amount of IgGs present on the
erythrocytes is far below to circulating IgGs in plasma. This
therefore, suggests that the association of IgGs anti-HIV to
erythrocytes has a relevant role in HIV availability in plasma but it
is not enough to significantly modify the quantification of IgGs
anti-HIV. Moreover, by enhancing HIV binding to erythrocytes,
the presence of HIV antibodies could play an important role in the
loss of infectivity, beyond its neutralizing capacity.
In conclusion, this study demonstrates the presence of IgG anti-
HIV associated to erythrocytes from HIV-positive individuals,
being the anti-gp160 and anti-p24 antibodies the most frequently
found. Moreover, erythrocytes from HIV-positive individuals
possess higher HIV capture capacity than erythrocytes from
HIV-negative individuals, and this is associated with the presence
of IgG anti-gp160/gp120 on erythrocyte membrane. In addition,
erythrocytes are capable to significantly reduce HIV infectivity in
plasma, but may keep infective virus bound to its membrane.
Finally, future studies in the erythrocyte-HIV relationship will
have a significant relevance for the understanding of HIV
pathogenesis and for the follow-up of patients.
Materials and Methods
Study Population
A total of 117 HIV-positive individuals older than 21 years of
age, who attended to the Argentinean National Reference Centre
for AIDS for pVL assessment, were invited to participate in this
study. The only inclusion criterion was that they must be HIV-
positive. Additionally, fifty-one HIV-negative individuals were
recruited as controls.
Ethics Statement
The protocol was approved by the local Ethics Committee of
Nexo AC Institutional Biomedical Review Board (IRB 00005349)
and conducted in compliance with all federal regulations
governing the protection of human subjects. A written informed
consent was signed by each participant.
Sample Processing
Samples were obtained by venous puncture using EDTA as
anti-coagulant. Erythrocytes were processed the day of blood
collection. Blood was centrifuged at 1,400 g for 10 minutes.
Plasma was stored for pVL and IgG anti-HIV determination. The
buffy coat was discarded. 1 ml of the erythrocyte-enriched fraction
was diluted 1/2 in PBS, followed by addition of Dextran 4% (MW
200,000–275,000) (Biochemical), mixed by inversion and kept in
vertical position for 30 minutes at RT. The erythrocyte sediment
was washed four times in PBS and in each wash, supernatant and
interface layers were aspirated and discarded. As control for the
washing process, the supernatant of the last erythrocyte wash (IgG
anti HIV-W) was taken to be used in IgG anti-HIV detection
assays.
Erythrocyte-associated Antibodies Release
Erythrocytes were subjected to acid treatment in order to
release erythrocyte-associated antibodies. Briefly, 750 ml glycine-
HCl buffer (pH 3.2) was added to 250 ml of purified erythrocytes
at RT and centrifuged at 470 g for 5 minutes. The supernatant
was neutralized to pH 7.2 with NaOH 0.1N and kept at 220uC.
The glycine-HCl treatment was also performed in plasma and in
supernatant of the last wash (IgG anti HIV-W) of each sample as
a control of erythrocyte washing.
In order to demonstrate selectivity in adherence between
antibodies and erythrocytes, we compared the IgG anti-HIV
pattern in plasma and erythrocyte at same concentration in eight
samples from HIV-positive individuals. The solution where IgGs
are released from erythrocytes to be measured was concentrated
100-fold (IgG anti-HIV-Ec) by the use of a microconcentrator
Amicon YM-10 (Millipore Corporation, Bedford, MA, USA). Less
than 33.3 mg/dl of total IgGs was found in this last solution, while
in plasma it ranged from 1,110 to 2,600 mg/dl. Therefore, plasma
was diluted at a final concentration equal to the extent in IgG in
erythrocytes (IgG anti HIV-Pd) and IgG anti-HIV were evaluated
by western blot.
Measurement of IgG, IgA and IgM was made by IMMAGE
Immunochemistry System (Beckman Coulter). Detection limit for
IgG was ,33.3 (mg/dL), for IgA it was ,6.67 (mg/dL) and for
IgM it was ,4.17(mg/dL). Reference range for plasma is IgG 50–
8,000 (mg/dL), IgA 95–385 (mg/dL) and IgM (mg/dL) 5–1,000.
All studied individuals were within the normal reference ranges for
IgG, IgA and IgM in plasma.
Antibodies Pattern Determination
Antibodies pattern was determined using anti-HIV antibody test
(New LAV Blot I Assay, BIO-RAD) in the following samples:
plasma (IgG anti-HIV-P), purified erythrocytes (IgG anti-HIV-E)
and the supernatant of the last erythrocyte washing (IgG anti HIV-
W).
Plasma Viral Load
Plasma viral load was assessed by branched DNA (b-DNA)
technology, with a detection limit of 50 HIV-1 RNA copies/ml
(Versant HIV-1 RNA 3.0, Bayer Co., Tarrytown, NY).
p24-antigen Determination
p24-antigen was quantified by ELISA (Murex HIV antigen
Mab, Abbott) as described by Garcia et al., 2011 [1].
MT-2 Cell Line
MT-2 cell line was obtained from the AIDS Research and
Reference Reagent Program. MT-2 cells are human T-cell
leukemia virus type I-transformed lymphoblastoid cell line. HIV-
1 strains IIIB is characteristic of syncytia formation when it infects
MT-2 cells. The in vitro 50% cell culture infectious dose (CCID50)
per milliliter for virus on MT-2 cells was determined by endpoint
dilution analysis (titer of HIV) by Reed & Muench method.
HIV Capture by Erythrocytes
PLOS ONE | www.plosone.org 8 September 2012 | Volume 7 | Issue 9 | e45808
Viral Stock
HIV-1 strain IIIB (HIV IIIB) was obtained from the AIDS
Research and Reference Reagent Program. An HIV IIIB strain
was replicated in MT-2 cells, and the viral stock enriched in viral
particles was obtained by centrifugation (23,500 g at 4uC during
60 minutes) of supernatants of MT-2 cells. Viruses quantification
was carried out by end-point dilution assay in MT-2 cells culture
(Cell Culture Infectious Dose 50%, CCID50), p24-antigen/ml and
viral load (copies HIV-RNA/ml) quantification.
Viral Capture Assay
4.108 erythrocytes were incubated with 60 pg p24-antigen of
particulate viral stock during 30 minutes at 37uC, at 40%
hematocrit. After centrifugation at 470 g for 5 minutes the
supernatant was recovered and p24-antigen was determined.
Capture of HIV by erythrocytes was determined by difference
between p24-antigen measurement before and after erythrocyte
incubation, with a correction that considered the liquid contained
in the erythrocyte fraction. Results were expressed as percentage
of HIV capture capacity by erythrocytes.
Previously, in order to choose the best procedure to determine
HIV capture by erythrocytes, two methods were compared. p24-
antigen was measured by: acid elution directly on the erythrocyte
fraction as was used in a previous work [1] and by difference as
was mentioned above. Linear regression between both methods
was made obtaining a R2 of 0.933 using 10 samples from HIV-
positive individuals. This analysis showed no significant difference
between both methods.
In order to rule out the possibility that the presence of
antibodies in the supernatant of the incubation (erythrocyte and
HIV) may mask the p24-antigen, previous to p24-antigen
measurement, the supernatant was heated for 3 min at 98uC (in
order to disaggregate possible immune complexes). Differences less
than 8% were observed in 10 cases between heated and unheated
supernatant. IgG anti-HIV antibodies were not detected in the
supernatant of the last wash of erythrocytes, after viral capture
assay.
To check if the p24-antigen measured in supernatants after
incubation (erythrocytes and HIV) did not come from erythrocytes
of HIV-positive individuals, viral capture assay was made in
erythrocytes without virus addition. p24-antigen was measured in
the supernatant after 30 minutes of incubation at 37uC and p24-
antigen was not detected.
Inhibition of Viral Capture Assay
Previous to the viral capture assay, erythrocytes from HIV-
positive individuals were incubated 30 minutes at 37uC with
7.7 mg/ml of HIV-1 gp120 glycoprotein. The viral capture assay
was performed after the washing of erythrocytes. The recombinant
gp120 used were gp120 IIIB (Protein Sciences and NIH AIDS
Research and Reference Reagent Program), gp120 MN and
gp120 CM (Protein Sciences). Presented data only shows the
results obtained for gp120 IIIB, although similar results were
obtained with the other two variants (data not shown).
Infectivity after Treatment with Antibodies and
Complement and Viral Capture
Plasma dilutions from HIV-positive individuals as source of
HIV-specific antibodies (Ig) were inactivated 45 minutes at 56uC.
100 ml of plasma from each individual was incubated with 10,000
CCID50 of CXCR4-tropic strains of HIV IIIB (HIV) for 30
minutes at 37uC in presence of: normal human serum as source of
complement (C) (HIV + Ig + C) or in presence of inactivated
normal human serum 45 minutes at 56uC (Ci) (HIV + Ig + Ci). An
aliquot of each of these samples were exposed to 2.5 108
erythrocytes from HIV-negative individuals (E) 30 minutes at
37uC (viral capture) (HIV-Ig-C + E or HIV-Ig-Ci + E). After
incubation, samples were centrifuged and the supernatants
collected. Then, MT-2 cells were infected with different dilutions
of these supernatants. After 1 hour, cultures were washed 3 times
and supplemented with medium. Cultures were incubated for 7 to
10 days and assayed for syncytium formation. Neutralization titers
were calculated, expressed as the inverse of the highest dilution
that is able to inhibit syncytium formation (loss of infectivity) in
MT-2 cells.
Virus alone without treatment, virus with complement and
without antibodies and virus with inactivated complement without
antibodies were used as controls. Moreover, the presence of
erythrocytes alone reduced the infectivity of the free virus available
and that effect was taking into account for the calculation of
neutralization titers.
Titers of HIV Infectivity after Viral Capture
2.5 108 erythrocytes from HIV-positive or negative individuals
were incubated with 10,000 CCID50 of CXCR4-tropic strains of
HIV IIIB (HIV) for 30 minutes at 37uC. After incubation, the
samples were centrifuged and the supernatant collected. The
infectivity remaining in the supernatants was measured by end-
point dilution assay in MT-2 cells culture (titers of infectious HIV).
Statistical Analysis
Fisher’s Exact Test was used to calculate significance in
contingency tables. Nonparametric methods were employed for
testing group differences, Mann-Whitney U test and Kruskal-
Wallis test for unpaired and Wilcoxon signed-rank test for paired.
Correlation analysis was performed using Spearman’s rank
correlation. All tests of significance were two-tailed and the level
of significance was set at 0.05. In order to show statistical
difference between means of HIV capture by erythrocytes of HIV-
positive and HIV-negative individuals t test was used.
Two-way ANOVA with random effects and repeated measures
analysis were used in the inhibition capture of HIV by erythrocytes
assays. For the former, treatment with soluble gp-120 was set as
a fixed factor and subjects under analysis were considered
a random factor. In this analysis a significant p-value for the
fixed factor means an association of the variable with the
treatment with gp-120 and a significant p-value for the random
factor means a significant variation of the association among
individuals under study. The repeated measures analysis was
applied when patients where further classified according to the
presence of antibodies against gp120 attached to erythrocytes,
considering this characteristic as the fixed factor and each of the
measures of percentage of capture with and without soluble gp-
120 as repeated measures over the same group of patients. For this
analysis, assumption of equality of covariance matrices were
assessed by Box’s Test, assumption of sphericity was assessed by
Mauchly’s Test, and assumption of equality of error variances was
assessed by Levene’s Test.
Supporting Information
Figure S1 Selective IgG anti-HIV adherence to erythro-
cytes. Pattern of immunoglobulin G anti-HIV (IgG anti-HIV)
determined by western blot in plasma of patients (IgG anti-HIV-
P), plasma diluted at the same concentration than 100x
concentrated IgG present in purified erythrocytes (IgG anti-
HIV-Pd), purified erythrocytes (IgG anti-HIV-E), and IgG anti-
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HIV-E 100x concentrated (IgG anti-HIV-Ec). Identical or similar
(difference in the presence of one to three IgG anti-HIV) patterns
were observed between IgG anti-HIV-E and IgG anti-HIV-Ec.
On the other hand, all IgG anti-HIV evaluated were found in
plasma while only one or two were observed in diluted plasmas.
Notably, we could not find an association between IgG anti-HIV
pattern in erythrocytes and diluted plasmas suggesting selective
IgG anti-HIV binding to erythrocyte membrane. Representative
IgG anti-HIV patterns from two of the eight HIV-positive
individuals evaluated are shown.
(TIF)
Table S1 Detection of IgGs anti-HIV, plasma viral load,
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